- Home
- Publications
- Publication Search
- Publication Details
Title
Chemotherapy in Pancreatic Cancer: A Systematic Review
Authors
Keywords
-
Journal
Medicina-Lithuania
Volume 54, Issue 3, Pages 48
Publisher
MDPI AG
Online
2018-07-11
DOI
10.3390/medicina54030048
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
- (2018) Rebecca Madden et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Radiofrequency assisted pancreaticoduodenectomy for palliative surgical resection of locally advanced pancreatic adenocarcinoma
- (2018) Jayant Kumar et al. Oncotarget
- A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
- (2017) Hee Seung Lee et al. MEDICINE
- DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
- (2016) Thomas J. Ettrich et al. BMC CANCER
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
- (2016) Stacey M Stein et al. BRITISH JOURNAL OF CANCER
- Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
- (2016) Hideki Ueno et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
- (2016) Hiroshi Imaoka et al. EUROPEAN JOURNAL OF CANCER
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial
- (2016) Lauren M. Postlewait et al. JOURNAL OF SURGICAL ONCOLOGY
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
- (2016) Katsuhiko Uesaka et al. LANCET
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma
- (2016) Cheng-Jeng Tai et al. MEDICINE
- Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
- (2016) Marwan Ghosn et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials
- (2016) Lola Rahib et al. JAMA Oncology
- A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2015) M. Ueno et al. ANNALS OF ONCOLOGY
- Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
- (2015) S Ohkawa et al. BRITISH JOURNAL OF CANCER
- Randomized clinical trial of adjuvant chemotherapy with S-1versusgemcitabine after pancreatic cancer resection
- (2015) M. Shimoda et al. BRITISH JOURNAL OF SURGERY
- Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
- (2015) Roberto Petrioli et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer
- (2015) Rory J. Makielski et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
- (2015) S. Kordes et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
- (2015) Takahiro Goji et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
- (2015) Zheng Wu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma
- (2015) Carmen Belli et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer
- (2015) L. Bergmann et al. EUROPEAN JOURNAL OF CANCER
- Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
- (2015) Timothy J. Hobday et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
- (2015) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
- (2015) Catherine Lombard-Bohas et al. PANCREAS
- A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma
- (2015) May Cho et al. HPB
- Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
- (2015) Jack P. Wang et al. Oncotarget
- Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
- (2015) Eric Assenat et al. Oncotarget
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
- (2014) Joseph M. Herman et al. CANCER
- Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma
- (2014) William H. Sherman et al. CANCER
- A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
- (2014) Kelvin Chan et al. PLoS One
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now